Enhanced Adaptive Immune Response Systems for MICA-Expressing Cancers
Legal Citation
Summary of the Inventive Concept
A next-generation system for adaptive immune response enhancement, integrating bi-specific T-cell engagers, machine learning-based dosing regimens, and nanoparticle-conjugated CAR-T cell therapies to combat MICA-expressing cancers.
Background and Problem Solved
The original patent disclosed anti-MICA antigen binding fragments, fusion molecules, and cells for treating MICA-expressing cancers. However, these approaches have limitations in terms of efficacy, safety, and personalized treatment. The new inventive concept addresses these limitations by introducing a multi-faceted system that adapts to individual patient needs and enhances anti-tumor activity.
Detailed Description of the Inventive Concept
The system comprises a bi-specific T-cell engager that directs T-cell effector responses against MICA-expressing cancer cells, a machine learning module for predicting optimal T-cell engager dosing regimens based on patient-specific genomic profiles, and a composition of matter featuring a MICA-targeting CAR-T cell and a bi-specific T-cell engager conjugated to a nanoparticle for enhanced tumor penetration. Additionally, the system includes a device for in vivo monitoring of MICA-expressing cancer cells and a computer-implemented method for identifying novel MICA-binding epitopes.
Novelty and Inventive Step
The new claims introduce a paradigm shift in cancer treatment by integrating machine learning, bi-specific T-cell engagers, and nanoparticle-conjugated CAR-T cell therapies. The inventive step lies in the combination of these components to create a personalized, adaptive, and highly effective system for combating MICA-expressing cancers.
Alternative Embodiments and Variations
Alternative embodiments may include variations in the bi-specific T-cell engager design, different nanoparticle conjugation strategies, and the integration of additional machine learning algorithms for predicting treatment outcomes. Variations may also include the use of different types of immune cells or targets, as well as the incorporation of gene editing technologies to enhance the system's efficacy.
Potential Commercial Applications and Market
The enhanced adaptive immune response system has significant commercial potential in the cancer treatment market, particularly for MICA-expressing cancers. The system's personalized and adaptive nature makes it an attractive solution for pharmaceutical companies, biotech startups, and healthcare providers seeking to improve patient outcomes and reduce treatment costs.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Immunotherapy, cancer treatment, cellular engineering, with expertise in chimeric antigen receptor (CAR) design, T-cell engineering, and molecular immunology
Person of Ordinary Skill (PHOSITA) Profile
A skilled researcher with a PhD in immunology or bioengineering, familiar with CAR-T cell technologies, monoclonal antibody design, and advanced computational biology techniques
Obviousness Rationale
A PHOSITA would recognize that the PTD represents a predictable extension of the source patent's MICA-targeting CAR technology by integrating machine learning, bi-specific engagement strategies, and nanoparticle delivery. The core innovation of targeting MICA-expressing cancer cells remains consistent, with the PTD adding computational and delivery enhancements that would be considered routine optimization in the field. The variations represent logical combinations of known immunotherapeutic techniques that a skilled practitioner would find obvious when seeking to improve cancer treatment strategies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,571 |
|---|---|
| Title | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
| Assignee(s) | The Trustees of Dartmouth College |